Search Results - "HAHNE, J. C"

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial by Smyth, E.C., Nyamundanda, G., Cunningham, D., Fontana, E., Ragulan, C., Tan, I.B., Lin, S.J., Wotherspoon, A., Nankivell, M., Fassan, M., Lampis, A., Hahne, J.C., Davies, A.R., Lagergren, J., Gossage, J.A., Maisey, N., Green, M., Zylstra, J.L., Allum, W.H., Langley, R.E., Tan, P., Valeri, N., Sadanandam, A.

“…Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph…”
Get full text

The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma by Rothhammer, T, Hahne, J C, Florin, A, Poser, I, Soncin, F, Wernert, N, Bosserhoff, A-K

“…The Ets-1 transcription factor plays a role in tumor vascularization and invasion by regulating expression of matrix-degrading proteases in endothelial cells…”
Get full text

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro by HAHNE, J.C, HONIG, A, MEYER, S.R, GAMBARYAN, S, WALTER, U, WISCHHUSEN, J, HÄUSSLER, S.F.M, SEGERER, S.E, FUJITA, N, DIETL, J, ENGEL, J.B

“…Platinum resistance is the most crucial problem for treatment of ovarian cancer. Increasing evidence points towards AKT overexpression as a mechanistic reason…”
Get full text

PI3K Inhibitor D-116883 is Effective in In Vitro Models of Ovarian Cancer by HONIG, A, HAHNE, J. C, MEYER, S, KRANKE, P, HAUSLER, S, DIESSNER, J, DIETL, J, ENGEL, J. B

“…D-116883 (Aeterna Zentaris GmbH, Frankfurt, Germany) is an orally effective drug that acts via inhibition of phosphatidylinositol 3-kinase (PI3K). The PI3K/AKT…”
Get full text

Peptidomimetic GnRH Antagonist AEZS-115 Inhibits the Growth of Ovarian and Endometrial Cancer Cells by ENGEL, J. B, HAHNE, J. C, HÄUSLER, S. F. M, MEYER, S, SEGERER, S. E, DIESSNER, J, DIETL, J, HONIG, A

“…AEZS-115 (Aeterna Zentaris GmbH, Frankfurt/M, Germany) is an orally active peptidomimetic antagonist of gonadotropin-releasing hormone (GnRH). In various…”
Get full text

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer by Lote, H., Spiteri, I., Ermini, L., Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J.C., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M., Werner, B., Lise, S., Aktipis, A., Maley, C., Greaves, M., Braconi, C., White, J., Fassan, M., Scarpa, A., Sottoriva, A., Valeri, N.

“…Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers…”
Get full text

Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers by Ratti, M., Valeri, N., Hahne, J.C., Lampis, A., Ghidini, M., Tomasello, G., Tanzi, G., Toppo, L., Pizzo, C., Donida, B., Senti, C., Salati, M., Trombatore, M., Fassan, M., Passalacqua, R.

Get full text

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial by Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J.C., Braconi, C., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., Gonzalez De Castro, D., Hulkki Wilson, S., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N.

“…Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T >…”
Get full text

EGFR amplification (amp) and survival in the REAL-3 trial by Smyth, E., Kouvelakis, K., Cunningham, D., Hahne, J.C., Peckitt, C., Vlachogiannis, G., Watkins, D., Rao, S., Starling, N., Wilson, S.H., Waddell, T.S., Okines, A., Crosby, T., Mansoor, W., Wadsley, J., Middleton, G., Wotherspoon, A., Chau, I., Valeri, N.

Get full text

Immunohistochemical quantification of lymph vessels, VEGF-C and VEGF receptor 3 in human sarcomas by Friedrichs, N, Hahne, J C, Pepper, M S, Rommerscheidt-Fuss, U, Stelzner, F, Buettner, R, Wernert, N

Get full text

Studies on the role of osteopontin-1 in endometrial cancer cell lines by Hahne, J.C., Meyer, S.R., Kranke, P., Dietl, J., Guckenberger, M., Polat, B., Hönig, A.

“…Background Osteopontin-1 is a well characterized protein in many tumour entities. Multiple roles in the processes invasion, metastasis and angiogenesis of…”
Get full text

Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production by Herchenröder, O, Hahne, J.C, Meyer, W.K.-H, Thiesen, H.-J, Schneider, J

“…The Krüppel-associated box (KRAB) domain has been described as a eukaryotic repressor of transcription. We show that fusion of KRAB to DNA-binding-domains…”
Get full text

Ets-1 Transcription Factor is Involved in Pterygial Angiogenesis by Naib-Majani, W, Breipohl, W, Shazli, E.E, Theuerkauf, I, Pleyer, U, Hahne, J.C, Wernert, N

“…Pterygial pathology is characterized by abnormal corneal epithelial proliferation, stromal modulation, matrix degradation and a strong tendency for otherwise…”
Get full text

1889PCirculating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease by Ghidini, M, Hahne, J C, Senti, C, Lampis, A, Ratti, M, Pizzo, C, Tomasello, G, Passalacqua, R, Valeri, N

“…Abstract Background Liquid biopsies (LB) allow monitoring of genetically different and co-occurring cancer cell clones. In metastatic colorectal cancer (mCRC),…”
Get full text

1953PDetection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients by Hahne, J C, Lampis, A, Ghidini, M, Ratti, M, Salati, M, Senti, C, Passalacqua, R, Cascione, L, Braconi, C, Sansom, O J, Fassan, M, Valeri, N

“…Abstract Background Monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) such as cetuximab or panitumumab are used for the treatment of…”
Get full text

646PEGFR amplification (amp) and survival in the REAL-3 trial by Smyth, E, Kouvelakis, K, Cunningham, D, Hahne, J C, Peckitt, C, Vlachogiannis, G, Watkins, D, Rao, S, Starling, N, Wilson, S H, Waddell, T S, Okines, A, Crosby, T, Mansoor, W, Wadsley, J, Middleton, G, Wotherspoon, A, Chau, I, Valeri, N

Get full text

688PCorrelation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers by Ratti, M, Valeri, N, Hahne, J C, Lampis, A, Ghidini, M, Tomasello, G, Tanzi, G, Toppo, L, Pizzo, C, Donida, B, Senti, C, Salati, M, Trombatore, M, Fassan, M, Passalacqua, R

Get full text

14PModulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage by Lampis, A, Carotenuto, P, Hedayat, S, Previdi, M C, Zito, D, Sclafani, F, Parisi, C, Hahne, J C, Hallsworth, A, Kirkin, V, Young, K, Kouvelakis, K, Azevedo, S X, Vasiliki, M, Scarpa, A, Cunningham, D, Chau, I, Valeri, N, Fassan, M, Braconi, C

“…Abstract Background FOLFIRINOX-regime is a combination-chemotherapy that provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC)…”
Get full text

Prognostic value of the immune-related transcriptome in biliary tract cancers by Ghidini, M., Cascione, L., Lampis, A., Pandolfo, R., Carotenuto, P., Trevisani, F., Hahne, J.C., Zito, D., Guzzardo, V., Zerbi, A., Torzilli, G., Roncalli, M., Rimassa, L., Santoro, A., Fassan, M., Valeri, N., Braconi, C.

Get full text

Intratumor morphologic and transcriptomic heterogeneity in V600E BRAF-mutated metastatic colorectal adenocarcinomas by Angerilli, V, Fontana, E, Lonardi, S, Sbaraglia, M, Borelli, B, Munari, G, Salmaso, R, Guzzardo, V, Spolverato, G, Pucciarelli, S, Pilati, P, Hahne, J C, Bergamo, F, Zagonel, V, Dei Tos, A P, Sadanandam, A, Loupakis, F, Valeri, N, Fassan, M

“…Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology,…”
Get full text